Literature DB >> 26829431

Assessing the risk factors for difficult-to-treat depression and treatment-resistant depression.

Bradley Gaynes1.   

Abstract

Depression is the leading cause of disability among people across the globe, according to the World Health Organization. Among those who have been diagnosed, many fail to achieve remission after following recommended antidepressant medication and psychosocial therapies. In particular, difficult-to-treat and treatment-resistant depression may cause severe impairments for patients, including diminished cognitive functioning, increased medical bills, and decreased workplace performance, as well as an increased risk of developing comorbid illnesses. However, many tools are available to clinicians for identifying treatment-resistant depression, including rating scales such as the 9-question Patient Health Questionnaire (PHQ-9) and the Quick Inventory of Depressive Symptomatology (QIDS-SR16), as well as clinical evidence related to risk factors for difficult-to-treat or treatment-resistant depression. Accurately identifying treatment-resistant depression is the first step toward changing treatment regimens to help patients achieve remission. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26829431     DOI: 10.4088/JCP.14077su1c.01

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

Review 2.  Astrocytes in depression and Alzheimer's disease.

Authors:  Yang Liao; Qu Xing; Qianqian Li; Jing Zhang; Ruiyuan Pan; Zengqiang Yuan
Journal:  Front Med       Date:  2021-11-23       Impact factor: 4.592

3.  Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice.

Authors:  Amaya Austrich-Olivares; María Salud García-Gutiérrez; Lucía Illescas; Ani Gasparyan; Jorge Manzanares
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

4.  Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study.

Authors:  Jörg Mahlich; Sunny Tsukazawa; Frank Wiegand
Journal:  Drugs Real World Outcomes       Date:  2018-03

5.  Treatment-Resistant Depression in Portugal: Perspective From Psychiatry Experts.

Authors:  João M Bessa; Serafim Carvalho; Inês B Cunha; Milene Fernandes; Ana Matos-Pires; Rui Neves; Albino J Oliveira-Maia; Susana Santos; Vítor Santos
Journal:  Front Psychiatry       Date:  2022-03-30       Impact factor: 4.157

6.  Barriers to depression care among middle-aged and older adults in Taiwan's universal healthcare system.

Authors:  Ting-Yu Chang; Shih-Cheng Liao; Chia-Ming Chang; Chi-Shin Wu; Wei-Lieh Huang; Juey-Jen Hwang; Chih-Cheng Hsu
Journal:  Lancet Reg Health West Pac       Date:  2022-06-04

7.  The influence of the enriched environment in different periods on neonatal maternal separation-induced visceral pain, anxiousness, and depressive behaviors.

Authors:  Ning-Ning Ji; Hong Jiang; Ming Xia
Journal:  Transl Pediatr       Date:  2022-09

8.  Sex-dependent effects of postweaning exposure to an enriched environment on visceral pain and anxiety- and depression-like behaviors induced by neonatal maternal separation.

Authors:  Ning-Ning Ji; Hong Jiang; Ming Xia
Journal:  Transl Pediatr       Date:  2022-09

9.  Folic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress.

Authors:  Yue Zhou; Yu Cong; Huan Liu
Journal:  BMC Neurosci       Date:  2020-01-15       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.